dc.contributor.author | Cicero, Sherri | |
dc.contributor.author | Kalayoglu Besisik, Sevgi | |
dc.contributor.author | Zhang, Lei | |
dc.contributor.author | Fu, Tommy | |
dc.contributor.author | Witzig, Thomas | |
dc.contributor.author | Goy, Andre | |
dc.contributor.author | Drach, Johannes | |
dc.contributor.author | Ramchandren, Radhakrishnan | |
dc.contributor.author | Robertson, Michael J. | |
dc.contributor.author | Avivi, Irit | |
dc.contributor.author | Rowe, Jacob M. | |
dc.contributor.author | Herbrecht, Raoul | |
dc.contributor.author | Van Hoof, Achiel | |
dc.date.accessioned | 2021-03-04T09:04:41Z | |
dc.date.available | 2021-03-04T09:04:41Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Goy A., Kalayoglu Besisik S., Drach J., Ramchandren R., Robertson M. J. , Avivi I., Rowe J. M. , Herbrecht R., Van Hoof A., Zhang L., et al., "Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.", British journal of haematology, cilt.170, sa.4, ss.496-503, 2015 | |
dc.identifier.issn | 0007-1048 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_668e5f8d-9f9a-4d81-8011-0cad90e24975 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/71213 | |
dc.identifier.uri | https://doi.org/10.1111/bjh.13456 | |
dc.description.abstract | Patients with mantle cell lymphoma (MCL) generally respond to first-line immunochemotherapy, but often show chemoresistance upon subsequent relapses, with poor outcome. Several studies of the immunomodulator, lenalidomide, have demonstrated its activity in MCL including the MCL-001 study in relapsed/refractory patients who had failed defined prior therapies of anthracyclines or mitoxantrone, cyclophosphamide, rituximab and also bortezomib. We present here the long-term efficacy follow-up of the prospective phase II MCL-001 study (N=134), including new exploratory analyses with baseline Ki-67 (MIB1), a biological marker of tumour proliferation. With longer follow-up, lenalidomide showed a 28% overall response rate [ORR; 8% complete response (CR)/CR unconfirmed (CRu)]. Median duration of response (DOR), progression-free survival and overall survival were 166, 40 and 209months, respectively. Myelosuppression continued to be the most common grade 3/4 toxicity. Several studies of MCL patients treated with chemotherapy, rituximab and bortezomib have shown an inverse association between survival and Ki-67. Ki-67 data in 81/134 MCL-001 patients showed similar ORRs in both low (<30% or <50%) versus high (30% or 50%) Ki-67-expressing groups, yet lower Ki-67 levels demonstrated superior CR/CRu, DOR and survival outcomes. Overall, lenalidomide showed durable efficacy with a consistent safety profile in heavily pretreated, relapsed/refractory MCL post-bortezomib. | |
dc.language.iso | eng | |
dc.subject | HEMATOLOJİ | |
dc.subject | İç Hastalıkları | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Hematoloji | |
dc.title | Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. | |
dc.type | Makale | |
dc.relation.journal | British journal of haematology | |
dc.contributor.department | Hackensack University Medical Center , , | |
dc.identifier.volume | 170 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 496 | |
dc.identifier.endpage | 503 | |
dc.contributor.firstauthorID | 223884 | |